{"id":31171,"date":"2026-01-27T12:01:46","date_gmt":"2026-01-27T11:01:46","guid":{"rendered":"https:\/\/dev8.id-interactive.fr\/new_unither\/?p=31171"},"modified":"2026-02-03T15:52:09","modified_gmt":"2026-02-03T14:52:09","slug":"construction-of-a-new-industrial-facility-in-gannat","status":"publish","type":"post","link":"https:\/\/dev8.id-interactive.fr\/new_unither\/construction-of-a-new-industrial-facility-in-gannat\/","title":{"rendered":"Construction of a New Industrial Facility in Gannat"},"content":{"rendered":"<div class=\"text-base my-auto mx-auto pb-10 px-4\">\n<div class=\"mx-auto max-w-3xl flex-1 flex flex-col\">\n<div class=\"markdown prose text-black w-full break-words\">\n<p><strong>PRESS RELEASE<\/strong><\/p>\n<p><strong>Unither Pharmaceuticals Launches Construction of a New Industrial Facility in Gannat<\/strong><\/p>\n<p>Gannat (Allier), January 22, 2026 \u2013 The pharmaceutical group Unither Pharmaceuticals is launching the construction of a new industrial facility at its Gannat (Allier) site.<\/p>\n<p>This project represents a total investment of more than \u20ac140 million and will lead to the creation of 133 direct jobs by 2028, and nearly 250 jobs by 2030.<br \/>\nIt aims to strengthen France\u2019s production capacities for sterile medical devices, in line with an industrial reshoring strategy, healthcare sovereignty, and local economic development.<\/p>\n<h3>A facility dedicated to innovative sterile technologies<\/h3>\n<p>The future facility will be dedicated to the manufacturing of:<\/p>\n<ul>\n<li>preservative-free sterile multidose systems (PF-MDS), a new activity for the site,<\/li>\n<li>sterile single-dose products using Blow-Fill-Seal (BFS) technology.<\/li>\n<\/ul>\n<p>The project will enable:<\/p>\n<ul>\n<li>a 40% increase in single-dose production capacity,<\/li>\n<li>an annual capacity of 30 million multidose units,<\/li>\n<li>diversification of the product offering, notably for essential ophthalmic products.<\/li>\n<\/ul>\n<p>\u201cThis investment is fully aligned with our industrial vision: developing sterile solutions that are safe, easy to use, and accessible, in order to make patients\u2019 lives easier,\u201d said \u00c9ric Goupil, Chairman and Chief Executive Officer of Unither Pharmaceuticals.<\/p>\n<h3>A structuring project for the local economy<\/h3>\n<p>Located close to the existing site, the new facility is part of a long-term industrial development strategy for the Bourbonnais region.<\/p>\n<p>Unither is relying on a local ecosystem involving:<\/p>\n<ul>\n<li>the Saint-Pour\u00e7ain Sioule Limagne Community of Municipalities,<\/li>\n<li>the Allier Department,<\/li>\n<li>local training organizations (IMT, APAVE, vocational high schools) to support skills development and industrial employment.<\/li>\n<\/ul>\n<h3>A project supported by the Auvergne-Rh\u00f4ne-Alpes Region<\/h3>\n<p>The project benefits from a \u20ac1.5 million grant awarded by the Auvergne-Rh\u00f4ne-Alpes Region under the \u201cPack Relocalisation \u2013 Supporting Industrial Investment\u201d scheme, approved on October 17, 2025.<\/p>\n<h3>An industrial partnership for the construction of the building<\/h3>\n<p>The design and construction of the building have been entrusted to GSE, a general contractor specialized in complex industrial projects.<\/p>\n<p>The future building, with a surface area of approximately 20,000 m\u00b2, will include ISO 5, 6 and 7 cleanrooms, laboratories, storage areas, and offices. It will meet regulatory requirements (ISO 13485, GMP) and incorporate RE2020 environmental standards, including a 700 kWp photovoltaic power plant.<\/p>\n<p>\u201cThis project makes it possible to deploy an ambitious environmental approach, integrating energy performance and low-carbon solutions, while meeting the stringent requirements of a pharmaceutical industrial site,\u201d emphasized Li\u00e8s Branche, Director, GSE Regions.<\/p>\n<h3>Timeline<\/h3>\n<ul>\n<li>Start of construction: March 2025<\/li>\n<li>Completion of construction: December 2026<\/li>\n<li>Start of industrial operations: from 2028<\/li>\n<li>First commercial launches: 2029<\/li>\n<\/ul>\n<h3>ABOUT UNITHER PHARMACEUTICALS<\/h3>\n<p>Unither Pharmaceuticals is an international pharmaceutical contract development and manufacturing organization (CDMO), specialized in liquid formulations in single-dose and multidose formats.<\/p>\n<p>The Group employs 2,300 people and operates eight manufacturing sites in France, the United States, Brazil, and China, as well as an R&amp;D center in France. In 2024, Unither Pharmaceuticals generated revenues of \u20ac522 million.<\/p>\n<p>More information: <a href=\"https:\/\/www.unither-pharma.fr\/\" target=\"_blank\" rel=\"noopener\">https:\/\/www.unither-pharma.fr\/<\/a><\/p>\n<h3>ABOUT GSE<\/h3>\n<p>Founded in 1976, GSE is a specialist in commercial real estate and turnkey industrial construction projects.<\/p>\n<p>More information: <a href=\"https:\/\/www.gsegroup.com\/\" target=\"_blank\" rel=\"noopener\">https:\/\/www.gsegroup.com\/<\/a><\/p>\n<h3>PRESS CONTACT<\/h3>\n<p><strong>Unither Pharmaceuticals \u2013 Elisabeth Alidou<\/strong><br \/>\nHead of Communications<br \/>\n<a href=\"mailto:press@unither-pharma.com\">press@unither-pharma.com<\/a> \/\/<br \/>\n<a href=\"https:\/\/www.unither-pharma.com\" target=\"_blank\" rel=\"noopener\">www.unither-pharma.com<\/a><\/p>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>PRESS RELEASE Unither Pharmaceuticals Launches Construction of a New Industrial Facility in Gannat Gannat (Allier), January 22, 2026 \u2013 The pharmaceutical group Unither Pharmaceuticals is launching the construction of a new industrial facility at its Gannat (Allier) site. This project represents a total investment of more than \u20ac140 million and will lead to the creation [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":31172,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[94],"tags":[],"class_list":["post-31171","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-corporate"],"acf":[],"_links":{"self":[{"href":"https:\/\/dev8.id-interactive.fr\/new_unither\/wp-json\/wp\/v2\/posts\/31171","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dev8.id-interactive.fr\/new_unither\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dev8.id-interactive.fr\/new_unither\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dev8.id-interactive.fr\/new_unither\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/dev8.id-interactive.fr\/new_unither\/wp-json\/wp\/v2\/comments?post=31171"}],"version-history":[{"count":4,"href":"https:\/\/dev8.id-interactive.fr\/new_unither\/wp-json\/wp\/v2\/posts\/31171\/revisions"}],"predecessor-version":[{"id":31179,"href":"https:\/\/dev8.id-interactive.fr\/new_unither\/wp-json\/wp\/v2\/posts\/31171\/revisions\/31179"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dev8.id-interactive.fr\/new_unither\/wp-json\/wp\/v2\/media\/31172"}],"wp:attachment":[{"href":"https:\/\/dev8.id-interactive.fr\/new_unither\/wp-json\/wp\/v2\/media?parent=31171"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dev8.id-interactive.fr\/new_unither\/wp-json\/wp\/v2\/categories?post=31171"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dev8.id-interactive.fr\/new_unither\/wp-json\/wp\/v2\/tags?post=31171"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}